Literature DB >> 11102776

Antigen-specific therapy for autoimmune disease.

L C Harrison1, D A Hafler.   

Abstract

The application of self-antigens as therapeutic tools is validated in inbred animal models of autoimmune disease. Mechanisms of antigen-induced tolerance (apoptosis, anergy, regulatory T cells and immune deviation) are being clarified in relation to the properties of antigens and the modes and routes of their delivery. Mucosa-mediated tolerance remains the predominant mode of antigen-specific therapy but awaits demonstration of clinical efficacy in human autoimmune disease.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11102776     DOI： 10.1016/s0952-7915(00)00166-7

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  26 in total

Review 1.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

4.  Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.

Authors:  Eliane Piaggio; Lennart T Mars; Cécile Cassan; Julie Cabarrocas; Maria Hofstätter; Sabine Desbois; Emilie Bergereau; Olaf Rötzschke; Kirsten Falk; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

5.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes.

Authors:  J S Petersen; S Bregenholt; V Apostolopolous; D Homann; T Wolfe; A Hughes; K De Jongh; M Wang; T Dyrberg; M G Von Herrath
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

8.  Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.

Authors:  Arno Hänninen; Nathan R Martinez; Gayle M Davey; William R Heath; Leonard C Harrison
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

9.  Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.

Authors:  G Fousteri; A Dave; A Bot; T Juntti; S Omid; M von Herrath
Journal:  Diabetologia       Date:  2010-05-20       Impact factor: 10.122

10.  Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

Authors:  Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.